{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:59:08Z","timestamp":1783699148054,"version":"3.55.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cushing syndrome (CS) as a state of prolonged cortisol excess is associated with multiple complications that contribute to increased mortality in affected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methodology<\/jats:title>\n                    <jats:p>This retrospective study presents data on etiology, demographic features, baseline cardiometabolic comorbidities, venous thromboembolic events and mortality of 214 consecutive CS patients from a single tertiary endocrinology center in Poland, a part of the European Register on Cushing\u2019s Syndrome (ERCUSYN). The group was predominated by pituitary CS (53%, PIT-CS), followed by adrenal CS (25%, ADR-CS) and ectopic CS (22%, ECT-CS). Statistica 13.0 was used to perform data analysis. Statistical significance was settled for a p-value \u22640.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The PIT-CS group was significantly younger than others. The PIT-CS and ADR-CS groups were predominated by women, contrary to the ECT-CS group, predominated by men. At the baseline, respectively 80%, 78%, and 66% of patients presented hypertension, dyslipidemia, and glucose metabolism impairments. Ischemic heart disease and heart failure were significantly more prevalent among ECT-CS. Venous thromboembolic events were present among 6% of patients. Overall mortality rate was 18%, and was higher in males than females (30% vs 15%; p&amp;lt;0.05), and was the highest in ECT-CS group (62%). The most common cause of death was tumor progression (55%) and infectious disease (26%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CS patients from our study presented a high number of comorbidities and high mortality rate. Some of the results were convergent with reports of the entire ERCUSYN database and other studies, while other results differed from the data reported in the literature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1785054","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:32:51Z","timestamp":1771997571000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cushing syndrome of different etiologies - cardiometabolic complications, venous thromboembolic events and mortality: data from ERCUSYN Krakow database"],"prefix":"10.3389","volume":"17","author":[{"given":"Mari","family":"Minasyan","sequence":"first","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Gamrat-\u017bmuda","sequence":"additional","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Bryk-Wi\u0105zania","sequence":"additional","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria","family":"Suchy","sequence":"additional","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bogus\u0142awska","sequence":"additional","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Rzepka","sequence":"additional","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Piwo\u0144ska-Solska","sequence":"additional","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Majka","sequence":"additional","affiliation":[{"name":"Students\u2019 Scientific Circle of the Department of Endocrinology, Jagiellonian University Medical College","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Hubalewska-Dydejczyk","sequence":"additional","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Valassi","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Hospital Germans Trias i Pujol","place":["Badalona, Barcelona, Spain"]},{"name":"Universitat Internacional de Catalunya (UIC)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Gilis-Januszewska","sequence":"additional","affiliation":[{"name":"Chair and Department of Endocrinology, Jagiellonian University Medical College","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00588-w","article-title":"Cushing syndrome","volume":"11","author":"Nieman","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e13114","DOI":"10.1111\/jne.13114","article-title":"Clinical presentation and etiology of Cushing\u2019s syndrome: Data from ERCUSYN","volume":"34","author":"Valassi","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.12","article-title":"Management of cushing disease","volume":"7","author":"Tritos","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing\u2019s syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01258-4","article-title":"Cardiovascular health and mortality in Cushing\u2019s disease","volume":"25","author":"Coulden","year":"2022","journal-title":"Pituitary"},{"key":"B7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000314213","article-title":"Pathophysiology of dyslipidemia in Cushing\u2019s syndrome","author":"Arnaldi","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05013.x","article-title":"Clinical features associated with glucocorticoid receptor polymorphisms","volume":"1179","author":"Manenschijn","year":"2009","journal-title":"overview. Ann N Y Acad Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2018.04.017","article-title":"The difficulties of pseudo-Cushing\u2019s syndrome (or \u201cnon-neoplastic hypercortisolism\u201d)","volume":"79","author":"Chabre","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EC-19-0435","article-title":"Approach to patients with pseudo-Cushing\u2019s states","volume":"9","author":"Scaroni","year":"2020","journal-title":"Endocr Connect"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0556","article-title":"Management of endocrine disease: Mortality remains increased in Cushing\u2019s disease despite biochemical remission: a systematic review and meta-analysis","volume":"172","author":"van Haalen","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00321","article-title":"The pathophysiology and treatment of hypertension in patients with cushing\u2019s syndrome","volume":"10","author":"Barbot","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e13175","DOI":"10.1111\/jne.13175","article-title":"Cardiovascular complications of Cushings syndrome: Impact on morbidity and mortality","volume":"34","author":"Clayton","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2021.1069","article-title":"Cushing syndrome associated myopathy: it is time for a change","volume":"36","author":"Reincke","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0689","article-title":"Persistence of myopathy in Cushing\u2019s syndrome: evaluation of the German Cushing\u2019s Registry","volume":"176","author":"Berr","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0967","article-title":"Diagnostic tests for Cushing\u2019s syndrome differ from published guidelines: data from ERCUSYN","volume":"176","author":"Valassi","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0074","article-title":"Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN","volume":"29","author":"Valassi","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/ejendo\/lvad008","article-title":"Cushing\u2019s syndrome in the elderly: data from the European Registry on Cushing\u2019s syndrome","volume":"188","author":"Amodru","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/ejendo\/lvad176","article-title":"High prevalence of venous thrombotic events in Cushing\u2019s syndrome: data from ERCUSYN and details in relation to surgery","volume":"190","author":"Isand","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13600","article-title":"Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing\u2019s disease than patients with cortisol producing adenoma. Data from the ERCUSYN","volume":"88","author":"Valassi","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0464","article-title":"High mortality within 90 days of diagnosis in patients with Cushing\u2019s syndrome: results from the ERCUSYN registry","volume":"181","author":"Valassi","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-17-0997","article-title":"Preoperative medical treatment in Cushing\u2019s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN","volume":"178","author":"Valassi","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-013-0396-7","article-title":"Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing\u2019s syndrome (ERCUSYN)","volume":"22","author":"Badia","year":"2013","journal-title":"Qual Life Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0272","article-title":"The European Registry on Cushing\u2019s syndrome: 2-year experience. Baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2012.03.035","article-title":"The value of a European registry for pituitary adenomas: the example of Cushing\u2019s syndrome registry","volume":"73","author":"Webb","year":"2012","journal-title":"Ann Endocrinol (Paris)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0242679","DOI":"10.1371\/journal.pone.0242679","article-title":"Ectopic ACTH syndrome of different origin-Diagnostic approach and clinical outcome. Experience of one Clinical Centre","volume":"15","author":"Pale\u0144-Tytko","year":"2020","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101611","article-title":"Ectopic cushing\u2019s syndrome in advanced small-cell lung cancer (SCLC): clinical challenges and therapeutic insights","volume":"17","author":"Gamrat-\u017bmuda","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-0984-8","article-title":"Cushing\u2019s disease: the burden of illness","volume":"56","author":"Pivonello","year":"2017","journal-title":"Endocrine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11102-025-01550-z","article-title":"Weight gain reversibility and BMI following treatment for Cushing\u2019s syndrome: long-term outcomes and potential predictors","volume":"28","author":"Sasson","year":"2025","journal-title":"Pituitary"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B31","article-title":"Screening for secondary endocrine hypertension in young patients","volume":"8","author":"Trifanescu","year":"2013","journal-title":"Maedica (Bucur)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02453-9","article-title":"Hypertension and Cushing\u2019s syndrome: hunt for the red flag","volume":"48","author":"Martino","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1159\/000314315","article-title":"Hypertension in Cushing\u2019s syndrome: from pathogenesis to treatment","author":"Cicala","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvz033","article-title":"Hypercoagulability in cushing syndrome, prevalence of thrombotic events: A large, single-center, retrospective study","volume":"4","author":"Suarez","year":"2019","journal-title":"J Endocr Soc"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.99.EP735","article-title":"Heart failure and its reversibility in patients with cushing\u2019s syndrome","volume":"99","author":"Kosharnaina","year":"2024","journal-title":"Endocrine Abstracts"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202002_20196","article-title":"High likelihood for atrial fibrillation in Cushing\u2019s syndrome","volume":"24","author":"Koracevic","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.600323","article-title":"Lipid abnormalities in patients with cushing\u2019s disease and its relationship with impaired glucose metabolism","volume":"11","author":"Sun","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00284","article-title":"Diabetes mellitus secondary to cushing\u2019s disease","volume":"9","author":"Barbot","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000537","article-title":"Glucose metabolism in Cushing\u2019s syndrome","volume":"27","author":"Sharma","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B40","article-title":"Chapter 3, Global picture","volume-title":"IDF DIABETES ATLAS","author":"Magliano","year":"2021"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-2376","article-title":"Global prevalence of prediabetes","volume":"46","author":"Rooney","year":"2023","journal-title":"Diabetes Care"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.5603\/cd.101189","article-title":"The prevalence of hypercortisolism in patients with type 2 diabetes and microvascular complications: A prospective observational case-control study","volume":"13","author":"Jusufovi\u0107","year":"2024","journal-title":"Clin Diabetology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.2337\/db25-0120","article-title":"Cushing syndrome, hypercortisolism, and glucose homeostasis: A review","volume":"74","author":"DeFronzo","year":"2025","journal-title":"Diabetes"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.2337\/dc25-1055","article-title":"Inadequately controlled type 2 diabetes and hypercortisolism: improved glycemia with mifepristone treatment","volume":"48","author":"DeFronzo","year":"2025","journal-title":"Diabetes Care"},{"key":"B45","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12020-016-1027-1","article-title":"Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors","volume":"56","author":"Tripodi","year":"2017","journal-title":"Endocrine"},{"key":"B46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12933-021-01372-w","article-title":"Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation","volume":"20","author":"Bryk-Wi\u0105zania","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00805","article-title":"Hypercoagulability and risk of venous thromboembolic events in endogenous cushing\u2019s syndrome: A systematic meta-analysis","volume":"9","author":"Wagner","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B48","author":"Hirsch","year":""},{"key":"B49","doi-asserted-by":"publisher","first-page":"e240046","DOI":"10.1530\/EC-24-0046","article-title":"Venous thromboembolism in Cushing syndrome: results from an EuRRECa and Endo-ERN survey","volume":"13","author":"Cherenko","year":"2024","journal-title":"Endocr Connect"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e230557","DOI":"10.1530\/EC-23-0557","article-title":"Patients with Cushing\u2019s syndrome suffer from provoked venous thromboembolism and are anticoagulated in various patterns","volume":"13","author":"Bryk-Wi\u0105zania","year":"2024","journal-title":"Endocr Connect"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2022.0083","article-title":"Pulmonary embolism as the first manifestation of Cushing syndrome in a young woman","volume":"73","author":"Minasyan","year":"2022","journal-title":"Endokrynol Pol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.16528","article-title":"Pulmonary embolism after delivery as the first manifestation of Cushing disease in pregnancy","volume":"133","author":"Minasyan","year":"2023","journal-title":"Pol Arch Intern Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa291","article-title":"Excess morbidity persists in patients with cushing\u2019s disease during long-term remission: A swedish nationwide study","volume":"105","author":"Papakokkinou","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021558","article-title":"Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing\u2019s disease during active disease and 1 year after disease remission","volume":"88","author":"Faggiano","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04055","article-title":"Metabolic and cardiovascular outcomes in patients with Cushing\u2019s syndrome of different aetiologies during active disease and 1 year after remission","volume":"75","author":"Giordano","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2957","article-title":"Outcome of Cushing\u2019s disease following transsphenoidal surgery in a single center over 20 years","volume":"97","author":"Hassan-Smith","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0569","article-title":"Mortality in Cushing\u2019s syndrome: systematic analysis of a large series with prolonged follow-up","volume":"169","author":"Ntali","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101521","article-title":"Epidemiology and mortality of Cushing\u2019s syndrome","volume":"35","author":"Hakami","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf059","article-title":"Mortality in Cushing\u2019s syndrome: declining over 2 decades but remaining higher than the general population","volume":"192","author":"Akirov","year":"2025","journal-title":"Eur J Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1785054\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:32:53Z","timestamp":1771997573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1785054\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":59,"alternative-id":["10.3389\/fendo.2026.1785054"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1785054","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"1785054"}}